The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | Real-world treatment patterns for HER2-amplified colorectal cancer
John Strickler, MD, Duke Cancer Institute, Durham, NC, comments on the how HER2-amplified colorectal cancer (CRC) is treated in real-world settings. Despite anti-HER2 therapies such as tucatinib and trastuzumab in current treatment guidelines, only approximately half of patients with HER2-amplified CRC are receiving the recommended treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
